Versant Ventures' New Biotechnology Incubator, Blueline Bioscience, Announces Collaboration in Canada

Versant Ventures' New Biotechnology Incubator, Blueline Bioscience, Announces 
Collaboration in Canada 
TORONTO, Nov. 20, 2013 /CNW/ - Blueline Bioscience, a Toronto-based biotech 
incubator launched by Versant Ventures in September of this year, today 
announced a collaboration with Celgene.  Blueline Bioscience is headquartered 
in the MaRS Discovery District of Toronto and works closely with leading 
academic and medical research centers in Canada to develop, fund, and grow 
early-stage biotechnology companies. 
Upon launch of new enterprises by Blueline Bioscience in areas of joint 
strategic interest such as oncology and inflammation, an affiliate of Celgene 
Corporation will have certain option rights through the collaboration. 
Stefan Larson, President of Blueline Bioscience and an 
Entrepreneur-in-Residence with Versant Ventures, stated: "We're excited to be 
tapping into a wealth of medical discoveries that we can work to translate 
from the laboratory into biotechnology products and companies. With the 
collaboration and option agreement now signed with Celgene, Blueline 
Bioscience is uniquely positioned in the life sciences community in Ontario." 
Blueline Bioscience is one of several efforts launched this year in Canada by 
Versant Ventures, including the establishment of a Versant office, the launch 
of an Inception Sciences drug discovery unit in Vancouver, and the execution 
of a significant deal with Bayer through Inception Sciences. Stefan Larson, 
a life sciences entrepreneur in Toronto, recently joined Versant as an 
Entrepreneur-in-Residence and President of Blueline Bioscience. Several 
Versant team members -- including Brad Bolzon, Ph.D., Jerel Davis, Ph.D., and 
Gianni Gromo, M.D., Ph.D. -- will be engaged in launching new enterprises with 
Blueline Bioscience. 
"Blueline Bioscience represents one of Versant's approaches to launching 
early-stage biotechnology companies in Canada," said Brad Bolzon, Managing 
Director at Versant Ventures. "We are very encouraged by the progress of the 
Blueline Bioscience team in identifying promising academic programs and 
launching such a strong collaboration. We look forward to growing and 
developing additional start-ups in Toronto." 
About Blueline Bioscience
Blueline Bioscience is a biotech incubator established by Versant Ventures in 
Toronto, Canada. Headquartered in the MaRS Discovery District of Toronto, 
Blueline Bioscience works with academic and medical researchers to translate 
discoveries into early-stage biotechnology companies. 
About Versant Ventures
Versant Ventures is a leading venture capital firm that invests in innovative, 
groundbreaking bio-pharmaceuticals, medical devices, and other life science 
opportunities. Founded in 1999, the firm consists of an experienced team 
committed to helping entrepreneurs build successful companies that impact 
healthcare and improve quality of life.
 

SOURCE  Versant Ventures / Blueline Bioscience 
 Stefan Larson President Blueline Bioscience slarson@bluelinebio.com 
416-637-8214  
David Climie VP Communications Hill + Knowlton Strategies 
david.climie@hkstrategies.ca 604-692-4234 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/November2013/20/c9031.html 
CO: Versant Ventures / Blueline Bioscience
ST: Ontario
NI: BTC VNT  
-0- Nov/20/2013 13:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.